Chemotherapy-induced nausea and vomiting

New England Journal of Medicine

Volumn 358, Issue 23, 2008, Pages 2482-

  Hesketh, Paul J ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CETUXIMAB; CLADRIBINE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IXABEPILONE; LAPATINIB; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PEMETREXED; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; FUNCTIONAL STATUS; HEALTH CARE; HUMAN; NAUSEA; NEOPLASM; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; VOMITING;

EID: 44849134443     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra0706547     Document Type: Review

References (96)

1. de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-61.
2. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97:2880-6.
3. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992;1:331-40.
4. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8.
5. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-36.
6. Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis: definition and validation of a predictive logistic model. Cancer 1989;64:1117-22.
7. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992;28:450-7.
8. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-9.
9. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of post-chemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997;15:116-23.
10. Roscoe JA, Bushunnow P, Morrow GR, et al. Patient experience is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 2004;101:2701-8.
11. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-6.
12. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
13. Roila F, Hesketh PJ, Herrstedt J, et al. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8.
14. Kris MG, Cubeddu LX, Gralla RJ, et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 1996;78:2193-8.
15. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-84.
16. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996;52:639-48.
17. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95.
18. 3 antiemetics. Support Care Cancer 1998;6:244-7.
19. Andrews PL, Rudd JA. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. In: Hesketh P, ed. Management of nausea and vomiting in cancer and cancer treatment. Boston: Jones and Bartlett, 2005:15-66.
20. Miller AD. Central mechanisms of vomiting. Dig Dis Sci 1999;44:Suppl:39S-43S.
21. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111:Suppl 8A:106S-112S.
22. Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 2006;129:3-16.
23. Wang SC, Borison HL. The vomiting center: a critical experimental analysis. Arch Neurol Psychiatry 1950;63:928-41.
24. Miller AD, Wilson VJ. "Vomiting center" reanalyzed: an electrical stimulation study. Brain Res 1983;270:154-8.
25. Miller AD, Grelot S. Neural control of respiratory muscle activation during vomiting. In: Miller AD, Bianchi AL, Bishop BP, eds. Neural control of the respiratory muscles, Boca Raton, FL: CRC Press, 1997:239-48.
26. Fukuda H, Koga T. Non-respiratory neurons in the Bötzinger complex exhibiting appropriate firing patterns to generate the emetic act in dogs. Neurosci Res 1992;14:180-94.
27. Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema to the pattern generator for the emetic act in dogs. Neurosci Res 1992;14:166-79.
28. Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990;68:325-45.
29. Andrews PL, Sanger GJ. Abdominal vagal afferent neurons: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol. 2002;2:650-6.
30. Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol 1994;15:301-20.
31. Borison HL. Area postrema: chemoreceptor circumventricular organ of the medulla oblongata. Prog Neurobiol 1989;32:351-90.
32. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 1989;97:247-55.
33. Carpenter DO, Briggs DB, Strominger N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol 1983;3:113-26.
34. Idem. Peptide-induced emesis in dogs. Behav Brain Res 1984;11:277-81.
35. Zagon A, Totterdell S, Jones RS. Direct projections from the ventrolateral medulla oblongata to the limbic forebrain: anterograde and retrograde tract-tracing studies in the rat. J Comp Neurol 1994;340:445-68.
36. Strominger NL, Knox AP, Carpenter DO. The connectivity of the area postrema in the ferret. Brain Res Bull 1994;33:33-47. Erratum, Brain Res Bull 1994;33(5):I.]
37. Horn CC, Ciucci M, Chaudhury A. Brain Fos expression during 48 h after cisplatin treatment: neural pathways for acute and delayed visceral sickness. Auton Neurosci 2007;132:44-51.
38. Leslie RA, Shah Y, Thejomayen M, Murphy KM, Robertson HA. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990;68:279-88.
39. Endo T, Minami M, Hirafuji M, et al. Neurochemistry and neuropharmacology of emesis - the role of serotonin. Toxicology 2000;153:189-201.
40. Moertel CG, Reitemeier RJ, Gage RP. A controlled clinical evaluation of anti-emetic drugs. JAMA 1963;186:116-8.
41. Saller R, Hellenbrecht D. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. Eur J Cancer Clin Oncol. 1986;22:1199-203.
42. Miner WD, Sanger GJ, Turner DH. Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 1987;56:159-62.
43. Fozard JR. Neuronal 5-HT receptors in the periphery. Neuropharmacology 1984;23:1473-86.
44. 3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 1989;159:157-64.
45. 3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol 1992;59:221-6.
46. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci 2003;91:87-94.
47. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev 2002;54:285-322.
48. Andrews PLR, Rudd JA. The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. In: Holzer P, ed. Handbook of experimental pharmacology. New York: Springer, 2004:359-440.
49. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1998;32:1-49.
50. Bountra C, Bunce K, Dale T, et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharamacol 1993;249(1):R3-R4.
51. Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993;250:R5-R6.
52. Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996;35:1121-9.
53. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21.
54. 3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Practice guideline report no. 12-3. Toronto: Cancer Care Ontario, 2003. (Accessed May 12, 2008, at http://www.cancercare.on.ca/pdf/pebc12_3f.pdf.)
55. del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301-8.
56. Jordan K, Hinke A, Grothey A, Schmoll HJ. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Support Care Cancer 2005;13:26-31.
57. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47. [Erratum, J Clin Oncol 2006;24:5341-2.]
58. Geling O, Eichler H-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-94.
59. Tonini G, Vincenzi B, Santini D. New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol 2005;1:143-9.
60. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7.
61. 3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-82.
62. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9.
63. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9.
64. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.
65. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-6.
66. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23: 2822-30. [Erratum, J Clin Oncol 2005;23:5851.]
67. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-10.
68. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55. [Erratum, Cancer 2006;106:1641.]
69. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004;32:1287-92.
70. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24.
71. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55:609-16.
72. Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59:407-12.
73. Depré M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61:341-6.
74. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 1981;7:11-4.
75. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994;12:596-600.
76. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
77. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer 1995;3:307-12.
78. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000;18:3409-22.
79. The Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998;16:2937-42.
80. Idem. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004;22:725-9. [Erratum, J Clin Oncol 2004;22:2038.]
81. Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 1983;25:Suppl 1:35-51.
82. Gralla RJ. Metoclopramide: a review of antiemetic trials. Drugs 1983;25:Suppl 1:63-73.
83. 3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 1990;26:Suppl 1:S8-S11.
84. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529-34.
85. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2007;15:1285-91.
86. Bowcock SJ, Stockdale AD, Bolton JA, Kang AA, Retsas S. Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. Br Med J (Clin Res Ed) 1984;288:1879.
87. Laszlo J, Clark RA, Hanson DC, Tyson L, Crumpler L, Gralla R. Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects. J Clin Oncol 1985;3:864-9.
88. Hesketh PJ, Gralla RJ, du Bois A, Tonato M. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 1998;6:221-7.
89. Ettinger DS, Bierman PJ, Bradbury B, et al. Antiemesis. J Natl Compr Canc Netw 2007;5:12-33.
90. Herrstedt J. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2007;18:Suppl 2:ii83-ii85.
91. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95:Suppl 2:2S-4S.
92. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112-6.
93. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005;13:80-4.
94. Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993;11:1384-90.
95. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993;328:1076-80.
96. Lebeau B, Depierre A, Giovannini M, et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 1997;8:887-92.